G. Fyfe
Genentech · 36 works · 15,414 citations · h-index 23
Top works
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
- Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
- Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
- Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus
- Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer
- Subcutaneous Administration of Interleukin‐2 in Human Immunodeficiency Virus Type 1—Infected Persons
- High-dose aldesleukin in renal cell carcinoma: long-term survival update.
- A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection
- 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma
- Outpatient Continuous Intravenous Interleukin‐2 or Subcutaneous, Polyethylene Glycol‐Modified Interleukin‐2 in Human Immunodeficiency Virus‐Infected Patients: A Randomized, Controlled, Multicenter Study
- Role of Sensitivity Analyses in Assessing Progression-Free Survival in Late-Stage Oncology Trials
- Beh?et syndrome
- Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease
- Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
- Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups
- Effects of cytochalasins B and D on alloxan inhibition of insulin release
- Subpopulations of B lymphocytes in germinal centers.
- Recombinant Human Thrombopoietin in Combination With Granulocyte Colony-Stimulating Factor Enhances Mobilization of Peripheral Blood Progenitor Cells, Increases Peripheral Blood Platelet Concentration, and Accelerates Hematopoietic Recovery Following High-Dose Chemotherapy